Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...

Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with ...

These companies could innovate their way to success.

CFOs, including Gunnar Wiedenfels of Warner Bros Discovery and Colette Kress of Nvidia, addressed disciplined spending, ...

A 9,000 percent rise since 2015 in overdose deaths involving fentanyl among adults over 65 is prompting a statewide effort to provide older adults with the information they need to age safely. An ...

The International Society for Stem Cell Research (ISSCR) today opened its sold-out international symposium, Accelerating ...

On November 18, 2025, ToolGen, Inc. (“ToolGen”) filed a complaint (“Complaint”) in the District of Massachusetts alleging infringement of its ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease ...